Axa’s Avidity Biosciences RNAM Stock Holding History

Axa’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-101,355	Closed	-$2.88M	–	836
2025 Q2	$2.88M	Buy	+101,355	New	+$3.02M	0.01%	689

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa's RNAM Position: Q3 2025 in Review

Axa sold out of Avidity Biosciences (RNAM) in Q3 2025, closing a stake of 101,355 shares — an estimated $2.88M sold.

Axa first reported a position in RNAM in Q2 2025 and held it in 1 quarter. The position peaked at $2.88M in Q2 2025. 272 funds tracked by Wall St. Rank hold RNAM as of Q3 2025.

Axa reported no remaining Avidity Biosciences position as of Q3 2025 after selling out during the quarter.
Axa sold 101,355 Avidity Biosciences shares in Q3 2025, an estimated $2.88M.
Axa first reported a position in Avidity Biosciences in Q2 2025 and held it in 1 quarter.
Axa's Avidity Biosciences position peaked at $2.88M in Q2 2025.
272 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.